Functional characteristics of lymphocytes and plasma cytokine profile of allogeneic hematopoietic stem cell recipients as risk factors for the development of acute graft-versus-host disease

It has been shown that in order to identify patients with high risk for developing immunological complications after allogeneic hematopoietic stem cell transplantation (alloHSCT), it is advisable to measure quantitatively the proliferative activity of lymphocytes in alloHSCT recipients on the day of transplantation. A high donor and recipient lymphocyte stimulation index (>11.55) is an unfavorable factor in terms of development of a graft-versus-host disease (GVHD) in the early posttransplant period. In the course of the work, it was found that the study of the cytokine profile of blood plasma of alloHSC recipients in the early posttransplant period can be used as an additional method for diagnosing GVHD. The levels of IL-8 and IL-21 in the blood plasma of alloHSC recipients can act as potential biomarkers of acute GVHD.

1. Kuzmina L. A., Petinati N. A., Vasilyeva V. A., Dovydenko M. V., Drokov M. Yu., Davydova Yu. O., Kapranov N. M., Sats N. V., Chabaeva Yu. A., Kulikov S. M., Gaponova T. V., Drize N. I., Parovichnikova E. N., Savchenko V. G. Multipotent mesenchymal stromal cells application for acute graft versus host disease treatment. Terapevticheskii arkhiv = Therapeutic archive, 2020, vol. 92, no. 7, pp. 23–30 (in Russian). https://doi.org/10.26442/00403660.2020.07.000757

2. von Dalowski F., Kramer M., Wermke M., Wehner R., Röllig C., Alakel N., Stölzel F., Parmentier S., Sockel K., Krech M., Schmitz M., Platzbecker U., Schetelig J., Bornhäuser M., von Bonin M. Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome. Stem Cells, 2016, vol. 34, no. 2, pp. 357–366. https://doi.org/10.1002/stem.2224

3. Couriel D., Caldera H., Champlin R., Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer, 2004, vol. 101, no. 9, pp. 1936–1946. https://doi.org/10.1002/cncr.20613

4. Arai S., Margolis J., Zahurak M., Anders V., Vogelsang G. B. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biology of Blood and Marrow Transplantation, 2002, vol. 8, no. 3, pp. 155–160. https://doi.org/10.1053/bbmt.2002.v8.pm11939605

5. Levine J. E., Logan B., Wu J., Alousi A. M., Ho V., Bolaños-Meade J., Weisdorf D. Graft-versus-host disease treatment: predictors of survival. Biology of Blood and Marrow Transplantation, 2010, vol. 16, no. 12, pp. 1693–1699. https://doi.org/10.1016/j.bbmt.2010.05.019

6. Westin J. R., Saliba R. M., De Lima M., Alousi A., Hosing C., Qazilbash M. H., Khouri I. F., Shpall E. J., Anderlini P., Rondon G., Andersson B. S., Champlin R., Couriel D. R. Steroid-refractory acute GVHD: predictors and outcomes. Advances in Hematology, 2011, vol. 2011, art. 601953. https://doi.org/10.1155/2011/601953

7. Efimov G. A., Vdovin A. S., Grigoryev A. A., Filkin S. Yu., Bykova N. A., Savchenko V. G. Immunobiology of acute graft-versus-host disease. Meditsinskaya immunologiya = Medical Immunology, 2015, vol. 17, no. 6, pp. 499–516 (in Russian). https://doi.org/10.15789/1563-0625-2015-6-499-516

8. Heemskerk M. B., van Walraven S. M., Cornelissen J. J., Barge R. M. Y., Bredius R. G. M., Egeler R. M., Tj Lie J. L., Révész T., Sintnicolaas K., Wulffraat N. M., Donker A. E., Hoogerbrugge P. M., van Rood J. J., Claas F. H. J., Oudshoorn M. How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more! Bone Marrow Transplant, 2005, vol. 35, pp. 645–652. https://doi.org/10.1038/sj.bmt.1704865

9. Miura Y., Thoburn C. J., Bright E. C., Chen W., Nakao S., Hess A. D. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. Blood, 2002, vol. 100, no. 7, pp. 2650–2658. https://doi.org/10.1182/blood-2002-01-0176

10. Yeh S. P., Liao Y. M., Lo W. J., Lin C. L., Bai L. Y., Lin C. Y., Hsieh C. Y., Chang Y. C., Huang Y. T., Chiu C. F. Kinetics of T helper subsets and associated cytokines correlate well with the clinical activity of graft-versus-host disease. PLoS One, 2012, vol. 7, no. 9, art. e44416. https://doi.org/10.1371/journal.pone.0044416

11. Hedrich C. M., Bream J. H. Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunologic Research, 2010, vol. 47, pp. 185–206. https://doi.org/10.1007/s12026-009-8150-5

12. Dlubek D., Turlej E., Sedzimirska M., Lange J., Lange A. Interleukin-17-producing cells increase among CD4+ lymphocytes before overt manifestation of acute graft-versus-host disease. Transplantation Proceedings, 2010, vol. 42, no. 8, pp. 3277–3279. https://doi.org/10.1016/j.transproceed.2010.07.026

13. Uguccioni M., Meliconi R., Nesci S., Lucarelli G., Ceska M., Gasbarrini G., Facchini A. Elevated interleukin-8 serum concentrations in beta-thalassemia and graft-versus-host disease. Blood, 1993, vol. 81, no. 9, pp. 2252–2256. https://doi.org/10.1182/blood.v81.9.2252.2252